Sharemaestro company-news research for EQT AB (publ) (EQT), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
STO
Sweden
Measured evidence
Company news sentiment
EQT news sentiment
EQT AB (publ)
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone59Neutral is 50
Constructive news tone
55/100 evidence confidence
100% direct company focus
2 current stories across 1 publishers
Current company news
News confirmed by price
Constructive news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.
Latest source headline Tencent, EU Fund Invest in AI Coding Startup Lovable at $13 Billion Valuation finance.yahoo.com · 12 Aug 2026 09:32What supports the read
2 current stories are mapped specifically to EQT.
Cross-story agreement is 99/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
59/100
Weighted toneConstructive news tone
55/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
99/100
Evidence agreement1/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth25
2.0 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness83
recency-weighted evidenceAgreement99
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment-trend disagreement
News subjects
What is shaping the score
Deals and strategy701 stories · 50%
Market update671 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com692 stories · 100%
Recurring subjects
Subjects appearing most often
Venture Capital1Startups1Rare Diseases1Funding1Financing1Coding1Clinical Trials1Biotech1AI1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#170Tone
finance.yahoo.comDirect company coverage
Tencent, EU Fund Invest in AI Coding Startup Lovable at $13 Billion Valuation
(Bloomberg) -- Swedish coding startup Lovable has raised funding at a $13.3 billion valuation, bringing in fresh capital to compete with larger rivals like Anthropic and Elon Musk's SpaceX. Most Read from Bloomberg Five Takeaways From Zuckerberg's 6,500-Word Manifesto on AI Phoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn't Drive Pakistan Says Deal Is Close Even as Iran, US Harden Stances Tata Sons Chairman to Step Down, Deepening Leadership Turmoil Trump Weighs Call for Capital Gains Tax Cuts as Midterm Boost The Stockholm-based company said on Wednesday that it completed a $
AICodingFundingStartupsVenture Capital
- Published
- 12 Aug 2026 09:32
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#267Tone
finance.yahoo.comDirect company coverage
EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
STOCKHOLM, Aug. 11, 2026 /PRNewswire/ -- EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company's USD 152 million Series B financing The financing will support the initiation of the global Phase 3 HEROIC study evaluating engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia, a rare genetic vascular disease characterized by severe nosebleeds, chronic anemia, and life-threatening vascular abnormalities, with no approved therapies EQT Life Sciences will draw on its experience supporting biotechnology companies through last-
BiotechClinical TrialsFinancingRare Diseases
- Published
- 11 Aug 2026 11:54
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.